Shire PLC (SHP) Insider Anne Minto Buys 190 Shares of Stock
Shire PLC (LON:SHP) insider Anne Minto purchased 190 shares of the stock in a transaction that occurred on Friday, September 29th. The stock was bought at an average cost of GBX 3,785 ($50.21) per share, for a total transaction of £7,191.50 ($9,539.06).
Shire PLC (SHP) opened at 3852.00 on Wednesday. Shire PLC has a 12 month low of GBX 3,603.50 and a 12 month high of GBX 5,331.00. The stock’s market capitalization is GBX 34.91 billion. The stock has a 50 day moving average price of GBX 3,847.72 and a 200 day moving average price of GBX 4,295.76.
The firm also recently announced a dividend, which will be paid on Friday, October 20th. Investors of record on Thursday, September 7th will be given a dividend of GBX 3.85 ($0.05) per share. The ex-dividend date is Thursday, September 7th. This represents a yield of 0.1%.
Several brokerages have weighed in on SHP. Deutsche Bank AG reissued a “buy” rating and set a GBX 6,000 ($79.59) price objective on shares of Shire PLC in a report on Friday, August 4th. HSBC Holdings plc raised Shire PLC to a “hold” rating and set a GBX 4,450 ($59.03) target price for the company in a research report on Thursday, July 6th. Shore Capital restated a “buy” rating on shares of Shire PLC in a research note on Wednesday, July 19th. Liberum Capital restated a “hold” rating and issued a GBX 4,900 ($65.00) target price on shares of Shire PLC in a research note on Tuesday, July 18th. Finally, Societe Generale reaffirmed a “buy” rating and set a GBX 7,500 ($99.48) price target on shares of Shire PLC in a research report on Wednesday, July 12th. Four research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of GBX 5,837.29 ($77.43).
About Shire PLC
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.